E Fund Management Co. Ltd. Makes New $579,000 Investment in Oruka Therapeutics, Inc. $ORKA

E Fund Management Co. Ltd. purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 6,079 shares of the company’s stock, valued at approximately $579,000.

A number of other hedge funds have also modified their holdings of ORKA. Legal & General Group Plc purchased a new stake in Oruka Therapeutics in the 2nd quarter valued at approximately $28,000. BNP Paribas Financial Markets increased its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the fourth quarter worth $37,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at $39,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $104.86 on Friday. The stock has a fifty day moving average of $91.06 and a two-hundred day moving average of $64.93. The company has a market capitalization of $6.94 billion, a PE ratio of -51.66 and a beta of -0.34. Oruka Therapeutics, Inc. has a fifty-two week low of $14.10 and a fifty-two week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the transaction, the insider owned 32,718 shares in the company, valued at $2,266,703.04. This trade represents a 19.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 83,116 shares of company stock valued at $6,636,533. 23.49% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on ORKA shares. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. HC Wainwright restated a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.